RxDoctor Payments Data

Stephanie Sanderson, PA

Physician Assistant · Lansdowne, VANPI 1275852071

Payments from drug & device makers

$7,809in general payments, 2019–2025

Across 347 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Collegium Pharmaceutical, Inc.$697
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$681
  • IBSA Pharma Inc.$534
  • Lundbeck LLC$451
  • Medtronic$414
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$7,809100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,809 in reported general payments places this provider in the 95th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$140,814
Medicare patients
394
Services billed
1,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate74$45,140
OxycontinOxycodone Hcl51$30,735
Buprenorphine112$29,761
BelbucaBuprenorphine Hcl24$19,470
Gabapentin591$9,295
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen375$8,845
Fentanyl77$7,461
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen265$6,190
Oxycodone Hcl324$5,655
Lidocaine49$4,907
Pregabalin148$3,369
Morphine Sulfate ErMorphine Sulfate133$2,986
Oxymorphone Hcl ErOxymorphone Hcl17$2,945
Celecoxib159$2,445
Duloxetine Hcl144$2,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$697$64,61098 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Lansdowne

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →